Gilead Sciences to Buy CymaBay Therapeutics for $4.3 Billion
Wall Street Journal
Gilead Sciences has agreed to buy CymaBay Therapeutics for $4.3 billion in a deal that expands Gilead’s liver portfolio.
https://www.wsj.com/articles/gilead-sciences-to-buy-cymabay-therapeutics-for-4-3-billion-4d295e69